Objective:

To evaluate the effectiveness of upadacitinib in reducing pain in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) compared to adalimumab and placebo.

Approach:

Key Findings:

• In RA, upadacitinib showed greater pain reduction than adalimumab and placebo, especially in patients with inflammation.
• In PsA, pain improvements with upadacitinib were similar to adalimumab in patients with inflammation attenuation.
• Upadacitinib led to higher rates of inflammation attenuation compared to adalimumab and placebo.

Interpretation:

Pain reduction occurred with and without inflammation control, indicating that upadacitinib's direct effects on pain are significant, especially in RA.

Limitations:

• Post hoc design of the study.
• Different trial designs for RA and PsA.
• Lack of early data in PsA.

Conclusion:

Upadacitinib is effective in reducing pain in RA and PsA, with notable direct effects independent of inflammation resolution.

Sources:

• RMD Open
Source

Based on findings from:

Upadacitinib and Pain in RA, PsA

Kathryn Wighton. MDSpire News, 2026.

https://news.mdspire.com/rheumatology/articles/upadacitinib-and-pain-in-ra-psa/

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.